Hans Huber

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.

Journal: The Journal of allergy and clinical immunology

Published: April 20, 2017

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Journal: Scientific reports

Published: April 05, 2017

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

Journal: EBioMedicine

Published: January 09, 2017

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Journal: EBioMedicine

Published: July 31, 2016

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Journal: The Journal of allergy and clinical immunology

Published: March 31, 2016

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Journal: The Journal of allergy and clinical immunology

Published: April 17, 2015

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

Journal: International archives of allergy and immunology

Published: August 07, 2014

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Journal: The Journal of allergy and clinical immunology

Published: February 07, 2014

Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergen-associated apple allergy.

Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergen-associated apple allergy.

Journal: The Journal of allergy and clinical immunology

Published: February 04, 2013

Recombinant house dust mite allergens.

Recombinant house dust mite allergens.

Journal: Methods (San Diego, Calif.)

Published: August 08, 2012

Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.

Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.

Journal: The Journal of allergy and clinical immunology

Published: February 16, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026